Adjuvant-free parenterally injectable vaccine platform that harnesses previously induced IgG as an antigen delivery carrier
Biochem Biophys Res Commun. 2024 Apr 7;711:149919. doi: 10.1016/j.bbrc.2024.149919. Online ahead of print.ABSTRACTSubunit vaccines are among the most useful vaccine modalities; however, their low immunogenicity necessitates the addition of adjuvants. Although adjuvants improve immune responses induced by vaccines, they often cause adverse reactions. To address this, we developed an adjuvant-free subunit vaccine platform that uses pre-existing antibodies generated from past infections or vaccinations as carriers for the delivery of vaccine antigens. Although we have confirmed the usefulness of this platform for nasal vaccin...
Source: Biochemical and Biophysical Research communications - April 12, 2024 Category: Biochemistry Authors: Atsushi Kawai Haruki Hirata Nagisa Tokunoh Chikako Ono Yoshiharu Matsuura Toshiro Hirai Yasuo Yoshioka Source Type: research
Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in Switzerland
CONCLUSIONS: These results demonstrate that using PCV15 among adults aged 65 years-and-above can prevent a substantial number of PD cases and deaths while remaining cost-effective over a range of inputs and scenarios.PMID:38609806 | DOI:10.1016/j.vaccine.2024.04.016 (Source: Vaccine)
Source: Vaccine - April 12, 2024 Category: Allergy & Immunology Authors: Kwame Owusu-Edusei Andrea Favre-Bulle Eleana Tsoumani Thomas Mutschler Nicole Cossrow Source Type: research
Effect of Regdanvimab on Mortality in Patients Infected with SARS-CoV-2 Delta Variants: A Propensity Score-Matched Cohort Study
ConclusionsWe showed that regdanvimab reduced the exacerbation rates of conditions and mortality in patients with the COVID-19 delta variant infection. Thus, it is recommended to streamline the drug approval system during epidemics of new variant viruses to improve the availability and usage of therapeutics for patients. To facilitate this, relevant institutional support is required. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - April 12, 2024 Category: Infectious Diseases Source Type: research
Reliance on sources of immunization information and vaccine uptake among older adults in a rural state: The mediating role of trust
Vaccine. 2024 Apr 10:S0264-410X(24)00444-4. doi: 10.1016/j.vaccine.2024.04.030. Online ahead of print.ABSTRACTOlder adults are more vulnerable to the negative impacts of infectious diseases than younger individuals. However, regardless of the importance and effectiveness of vaccines to reduce morbidity and mortality, issues remain with vaccine hesitancy among this population. Older adults' sources of immunization information and their level of trust in those sources may play a role in their vaccination behaviors. This research aimed to better understand the role of information sources and related issues of trust as related...
Source: Vaccine - April 11, 2024 Category: Allergy & Immunology Authors: Andrea L Huseth-Zosel Heather Fuller Alexandria Hicks Paul J Carson Source Type: research
Reliance on sources of immunization information and vaccine uptake among older adults in a rural state: The mediating role of trust
Vaccine. 2024 Apr 10:S0264-410X(24)00444-4. doi: 10.1016/j.vaccine.2024.04.030. Online ahead of print.ABSTRACTOlder adults are more vulnerable to the negative impacts of infectious diseases than younger individuals. However, regardless of the importance and effectiveness of vaccines to reduce morbidity and mortality, issues remain with vaccine hesitancy among this population. Older adults' sources of immunization information and their level of trust in those sources may play a role in their vaccination behaviors. This research aimed to better understand the role of information sources and related issues of trust as related...
Source: Vaccine - April 11, 2024 Category: Allergy & Immunology Authors: Andrea L Huseth-Zosel Heather Fuller Alexandria Hicks Paul J Carson Source Type: research
Vaccines in cardiology, an underutilized strategy to reduce the residual cardiovascular risk
Arch Peru Cardiol Cir Cardiovasc. 2024 Mar 19;5(1):29-39. doi: 10.47487/apcyccv.v5i1.349. eCollection 2024 Jan-Mar.ABSTRACTCardiovascular diseases stand as the leading cause of mortality among adults globally. For decades, comprehensive evidence has underscored the correlation between infections, particularly those involving the respiratory system, and an elevated risk of cardiovascular and cerebrovascular events, as well as all-cause mortality. The mechanisms through which infections heighten cardiovascular events are intricate, encompassing immune system activation, systemic inflammation, hypercoagulable states, sympathe...
Source: Herpes - April 10, 2024 Category: Infectious Diseases Authors: Sebasti án García-Zamora Laura Pulido Source Type: research
Enhancing Immune Response in Non-Small-Cell Lung Cancer Patients: Impact of the 13-Valent Pneumococcal Conjugate Vaccine
Conclusions: We hope that our research will contribute to increasing patients' and physicians' awareness of the importance of including PCV13 vaccinations in the standard of oncological care, which will extend the survival time of patients and improve their quality of life.PMID:38592328 | DOI:10.3390/jcm13051520 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 9, 2024 Category: Cancer & Oncology Authors: Jolanta Smok-Kalwat Paulina Mertowska Izabela Korona-G łowniak Sebastian Mertowski Paulina Nied źwiedzka-Rystwej Dominika B ębnowska Krzysztof Gosik Andrzej Stepulak Stanis ław Góźdź Jacek Roli ński Zofia G órecka Jan Siwiec Ewelina Grywalska Source Type: research
Protective effect of PCV13 against all-cause hospitalized pneumonia in children in Beijing, China: real-world evidence
CONCLUSIONS: PCV13 had a certain protective effect on all-cause hospitalized pneumonia, and the booster immunization strategy had the best protective effect with great public health significance to enter the immunization program.PMID:38594120 | DOI:10.1016/j.vaccine.2024.04.015 (Source: Vaccine)
Source: Vaccine - April 9, 2024 Category: Allergy & Immunology Authors: Min Lv Juan Du Ming-Zhu Xie Yiguo Zhou Guangzhao Yang Jian Wang Wan-Xue Zhang Han Yang Shan-Shan Zhang Fuqiang Cui Qing-Bin Lu Jiang Wu Source Type: research
Childhood vaccination coverage and regional differences in Swiss birth cohorts 2012-2021: Are we on track?
CONCLUSION: Full vaccination coverage in Swiss children is still below 90 % with many vaccinations administered delayed. Given regional differences, missed or delayed booster vaccinations, and differences in vaccine-specific acceptability, more effort may be needed to achieve national vaccination targets.PMID:38593195 | DOI:10.1016/j.vaccine.2023.10.043 (Source: Vaccine)
Source: Vaccine - April 9, 2024 Category: Allergy & Immunology Authors: Simeon J Z ürcher Andri Signorell Anja L échot-Huser Christoph Aebi Carola A Huber Source Type: research
Enhancing Immune Response in Non-Small-Cell Lung Cancer Patients: Impact of the 13-Valent Pneumococcal Conjugate Vaccine
Conclusions: We hope that our research will contribute to increasing patients' and physicians' awareness of the importance of including PCV13 vaccinations in the standard of oncological care, which will extend the survival time of patients and improve their quality of life.PMID:38592328 | PMC:PMC10933946 | DOI:10.3390/jcm13051520 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 9, 2024 Category: Cancer & Oncology Authors: Jolanta Smok-Kalwat Paulina Mertowska Izabela Korona-G łowniak Sebastian Mertowski Paulina Nied źwiedzka-Rystwej Dominika B ębnowska Krzysztof Gosik Andrzej Stepulak Stanis ław Góźdź Jacek Roli ński Zofia G órecka Jan Siwiec Ewelina Grywalska Source Type: research
Adherence to Advisory Committee on Immunization Practices in diabetes mellitus patients in Saudi Arabia: A multicenter retrospective study
CONCLUSION: In Saudi Arabia, patients with DM showed higher vaccination rates for annual influenza and COVID-19 vaccines compared to other vaccinations such as herpes zoster, Tdap, pneumococcal, and HPV. Factors such as vaccine recommendations provided by family physicians or specialists, the site of care, income level, DM-related hospitalization history, residency site, HbA1c level, and health sector type can significantly influence the vaccination rate in patients with DM.PMID:38591075 | PMC:PMC10999047 | DOI:10.4239/wjd.v15.i3.440 (Source: Herpes)
Source: Herpes - April 9, 2024 Category: Infectious Diseases Authors: Saleh Fahad Alqifari Aya K Esmail Dalal M Alarifi Ghalya Y Alsuliman Maram M Alhati May R Mutlaq Mohammed Aldhaeefi Shaden A Alshuaibi Palanisamy Amirthalingam Abrar Abdallah Afaf S Wasel Heba R Hamad Shoroq Alamin Tasneem H Atia Tariq Alqahtani Source Type: research
Protective effect of PCV13 against all-cause hospitalized pneumonia in children in Beijing, China: real-world evidence
CONCLUSIONS: PCV13 had a certain protective effect on all-cause hospitalized pneumonia, and the booster immunization strategy had the best protective effect with great public health significance to enter the immunization program.PMID:38594120 | DOI:10.1016/j.vaccine.2024.04.015 (Source: Vaccine)
Source: Vaccine - April 9, 2024 Category: Allergy & Immunology Authors: Min Lv Juan Du Ming-Zhu Xie Yiguo Zhou Guangzhao Yang Jian Wang Wan-Xue Zhang Han Yang Shan-Shan Zhang Fuqiang Cui Qing-Bin Lu Jiang Wu Source Type: research
Childhood vaccination coverage and regional differences in Swiss birth cohorts 2012-2021: Are we on track?
CONCLUSION: Full vaccination coverage in Swiss children is still below 90 % with many vaccinations administered delayed. Given regional differences, missed or delayed booster vaccinations, and differences in vaccine-specific acceptability, more effort may be needed to achieve national vaccination targets.PMID:38593195 | DOI:10.1016/j.vaccine.2023.10.043 (Source: Vaccine)
Source: Vaccine - April 9, 2024 Category: Allergy & Immunology Authors: Simeon J Z ürcher Andri Signorell Anja L échot-Huser Christoph Aebi Carola A Huber Source Type: research
Mutations in the F protein of the live-attenuated respiratory syncytial virus vaccine candidate ΔNS2/Δ1313/I1314L increase the stability of infectivity and content of prefusion F protein
by Judith Alamares-Sapuay, Michael Kishko, Charles Lai, Mark Parrington, Simon Delagrave, Richard Herbert, Ashley Castens, Joanna Swerczek, Cindy Luongo, Lijuan Yang, Peter L. Collins, Ursula J. Buchholz, Linong Zhang
Respiratory syncytial virus (RSV) is the leading viral cause of bronchiolitis and pneumonia in infants and toddlers, but there currently is no licensed pediatric vaccine. A leading vaccine candidate that has been evaluated for intranasal immunization in a recently completed phase 1/2 clinical tria l is an attenuated version of RSV strain A2 called RSV/ΔNS2/Δ1313/I1314L (hereafter called ΔNS2). ΔNS2 is at...
Source: PLoS One - April 9, 2024 Category: Biomedical Science Authors: Judith Alamares-Sapuay Source Type: research
